ICER slightly softens its recommendation on Pfizer's ATTR-CM drug price
A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as Vyndamax and Vyndaqel, should be priced annually, but it’s still...
View ArticleLawyers predict Biosecure passage in Congress' lame duck session
BETHESDA, MD — A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the congressional “lame duck” period between the election and the...
View ArticleStarboard says Kenvue skin and beauty lines need to be reinvigorated
Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — Johnson & Johnson’s consumer spinout Kenvue. In a presentation Tuesday at...
View ArticleAmgen preps to launch Eylea biosimilar years early after Regeneron loses appeal
Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron’s blockbuster Eylea, following an appeals court decision that ruled against competitor Regeneron. “We look forward to...
View ArticleClik here to view.
Be Bio raises $82M for work on B cell therapy in hemophilia B
Be Bio’s $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in development, including the first-ever B cell therapy to enter human studies for...
View ArticleSenators question whether Pfizer, Eli Lilly telehealth platforms violate law
Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may lead to inappropriate prescribing. In two letters dated Monday, the lawmakers...
View ArticleOcuphire and Opus Genetics merge in all-stock ophthalmology deal
The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints News. Ocuphire $OCUP will acquire privately-held Opus and adopt its name, and...
View ArticleClik here to view.
Sangamo to seek accelerated approval for Fabry gene therapy
Sangamo Therapeutics thinks it’s found a faster, earlier pathway to approval for its Fabry disease gene therapy. The biotech announced Tuesday that it plans to seek an accelerated approval from the FDA...
View ArticleRoche says it is undeterred by upcoming biosimilar threat to Vabysmo
Roche’s competition in the eye disease space is intensifying with Regeneron’s high-dose Eylea and a looming biosimilar challenge, but the Swiss pharma said its blockbuster eye drug Vabysmo is holding...
View ArticleMerck acquires Modifi Bio and brain cancer assets for $30M
Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against chemotherapy-resistant glioblastoma, a devastating and often deadly disease. Merck will...
View ArticleClik here to view.
UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake
Eli Lilly’s Alzheimer’s drug Kisunla is likely to face an uphill uptake battle in the UK after its local cost-effectiveness watchdog NICE said it “cannot currently be considered good value for the...
View ArticleHouston startup March Biosciences raises $28M Series A to get CAR-T into Phase 2
A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March Biosciences, will enter Phase 2 early next year with an autologous CAR-T cell...
View ArticleLife sciences investor Dimension targets $500M second fund
A venture capital firm that seeks to digitize the life sciences ecosystem has plans for a $500 million follow-up fund, according to a Tuesday SEC filing. The firm, Dimension Capital, debuted in January...
View ArticleRadiopharma biotech Alpha-9 Oncology closes $175M Series C fundraise
Another private radiopharmaceutical biotech has raised big money. Alpha-9 Oncology revealed on Wednesday that it’s put together a $175 million Series C, aiming to fund clinical trials for programs that...
View ArticleClik here to view.
Alto Neuroscience's mid-stage trial misses primary endpoint in depression
Alto Neuroscience’s stock tumbled 60% on Wednesday morning, the day after the company said a mid-stage trial for its oral small molecule failed to improve symptoms of major depressive disorder. In the...
View ArticleEccogene gets $60M from AstraZeneca; Evotec also records milestone with BMS
Plus, news about DBV, Double Point Ventures and Lumos: Eccogene’s $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first patient in a...
View ArticleThermo Fisher predicts revenue uptick in 2025 as it expects headwinds to ease
Thermo Fisher told investors it is ready to shut the door on 2024, anticipating biotech funding to improve and lingering business insecurity caused by the Covid-19 pandemic to dissipate in 2025....
View ArticleClik here to view.
Obesity drug manufacturing deal shouldn't close, Roche CEO says
Antitrust regulators shouldn’t clear Novo Holdings’ planned acquisition of Catalent, Roche CEO Thomas Schinecker said Wednesday, adding to the pressure that industry competitors appear to be trying to...
View ArticleNovo Nordisk asks FDA to prohibit semaglutide compounding, following Eli Lilly
Novo Nordisk has asked the FDA to prohibit the compounding of semaglutide, ramping up the company’s fight against pharmacies distributing their own versions of the blockbuster weight loss and diabetes...
View ArticleFDA approves Pfizer's RSV vaccine for higher-risk adults
Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval this week. The shot, Abrysvo, is now approved for people 18 to 59 who are at...
View Article